Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

Parkinson's disease (PD) is a disabling neurodegenerative disease that affects approximately 10 million people worldwide, ...

Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.

Research into treatment using induced pluripotent stem (iPS) cells has been generating positive results one after another.

Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) ...

Congratulations to Karl-Johan Malmberg, who has been awarded King Olav V's Cancer Research Prize for 2025. The prize is ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and poster ...

Developed at the Children's Hospital of Philadelphia (CHOP) and called Zynteglo, the medicine uses the patient's own stem ...

Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for ...

Fujifilm Cellular Dynamics Inc., a developer and manufacturer of human induced pluripotent stem cells, has appointed Delara Motlagh as COO.